The distortionary effects of government procurement: Evidence from Medicaid prescription drug purchasing

Quarterly Journal of Economics

Volumn 121, Issue 1, 2006, Pages 1-30

  Duggan, Mark ^a   Scott Morton, Fiona M ^b  

^a UNIVERSITY OF MARYLAND   (United States)

^b YALE SCHOOL OF MANAGEMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33644870984     PISSN: 00335533     EISSN: 15314650     Source Type: Journal    
DOI: 10.1162/qjec.2006.121.1.1     Document Type: Article

References (28)

1. Aldridge, Christopher, and Arnold Doyle, "AIDS Drug Assistance Programs -Getting the Best Price?" mimeo, National AIDS Drug Assistance Program Monitoring Project, April 2002.
2. Averch, Harvey, and Leland Johnson, "Behavior of the Firm under Regulatory Constraint," American Economic Review, LII (1962), 1052-1069.
3. Borrell, Joan-Ramon, "Pharmaceutical Price Regulation - A Study on the Impact of the Rate-of-Return Regulation in the UK," PharmacoEconomics, XV (1999), 291-303.
4. Currie, Janet, and Jeffrey Grogger, "Medicaid Expansions and Welfare Contractions: Offsetting Effects on Prenatal Care and Infant Health?" Journal of Health Economics, XXI (2002), 313-335.
5. Cutler, David, and Jonathan Gruber, "Does Public Insurance Crowd Out Private Insurance?" Quarterly Journal of Economics, CXI (1996), 391-430.
6. Duggan, Mark, "Do New Prescription Drugs Pay Pay Themselves? The Case of Second-Generation Antipsychotics," Journal of Health Economics, XXIV (2005), 1-31.
7. Duggan, Mark, and William Evans, "Estimating the Impact of Medical Innovation: The Case of HIV Antiretroviral Treatments," NBER Working Paper No. 11109, Cambridge, MA, National Bureau of Economic Research, 2005.
8. Duggan, Mark, and Fiona Scott Morton, "The Distortionary Effects of Government Procurement: Evidence from Medicaid Prescription Drug Purchasing," NBER Working Paper No. 10930, Cambridge, MA, National Bureau of Economic Research, 2004.
9. Epstein, Arnold, and Joseph Newhouse, "The Impact of Medicaid Expansions on Early Prenatal Care and Health Outcomes," Health Care Financing Review, XIX (1998), 85-99.
10. Finkelstein, Amy, "Static and Dynamic Effects of Health Policy: Evidence from the Vaccine Industry," Quarterly Journal of Economics, CXIX (2004), 527-564.
11. Frank, Richard G., and David S. Salkever, "Pricing, Patent Loss and the Market for Pharmaceuticals," Southern Economic Journal, LIX (1992), 165-179.
12. Frank, Richard G., and David S. Salkever, "Generic Entry and the Pricing of Pharmaceuticals," Journal of Economics and Management Strategy, VI (1997), 75-90.
13. Gruber, Jonathan, "Medicaid," in R. Moffitt, ed., Means-Tested Transfer Programs in the United States (Chicago, IL: University of Chicago Press, 2003).
14. Gruber, Jonathan, and Aaron Yelowitz, "Public Health Insurance and Private Saving," Journal of Political Economy, CVII (1999), 1249-1274.
15. Holmstrom, Bengt, and Paul Milgrom, "Multitask Principal-Agent Analyses: Incentive Contracts, Asset Ownership, and Job Design," Journal of Law, Economics, and Organization, VII (1991), 24-52.
16. Ikegami, Naoki, Shunya Ikeda, and Hiroki Kawai, "Why Medical Care Costs in Japan Have Increased Despite Declining Prices for Pharmaceuticals, " Pharmoeconomics, XIV (1998), 97-105.
17. Kaiser Commission on Medicaid and the Uninsured, "Medicaid Outpatient Prescription Drug Benefits: Findings from a National Survey and Selected Case Study Highlights," Menlo Park: Kaiser Family Foundation, 2001.
18. _, "Medicaid Enrollment and Spending Trends," Menlo Park: Kaiser Family Foundation, 2005.
19. Laffont, Jean-Jacques, and Jean Tirole, A Theory of Incentives in Procurement and Regulation (Cambridge, MA: MIT Press, 1993).
20. Martinez, Barbara, "Drug-Price Surge May Erode Savings from Medicare Card," Wall Street Journal, March 24, 2004, page B1.
21. National Institute for Health Care Management, "Prescription Drug Expenditures in 2001: Another Year of Escalating Costs," mimeo, 2002.
22. Newhouse, Joseph, "How Much Should Medicare Pay for Prescription Drugs?" Health Affairs, XXIII (2004), 89-102.
23. Olson, Mary, "Substitution in Regulatory Agencies: FDA Enforcement Alternatives," Journal of Law, Economics, and Organization, XII (1996), 376-407.
24. Parker, David, "The Performance of BAA Before and After Privatization - A DEA Study," Journal of Transport Economics and Policy, XXXIII (1999), 133-145.
25. Scott Morton, Fiona, "The Strategic Response by Pharmaceutical Firms to the Medicaid Most-Favored-Customer Rules," RAND Journal of Economics, XXVIII (1997), 269-290.
26. Tirole, Jean, The Theory of Industrial Organization (Cambridge, MA: MIT Press, 1991).
27. Yelowitz, Aaron, "The Medicaid Notch, Labor Supply, and Welfare Participation: Evidence from Eligibility Expansions," Quarterly Journal of Economics, CV (1995), 909-940.
28. _, "Why Did the SSI Disabled Program Grow So Much? Disentangling the Effect of Medicaid," Journal of Health Economics, XVII (1998), 321-349.